Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial
Movement Disorders · 2025-12 · 40 (12) · 2688-2699
DOI: 10.1002/mds.70028 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 01.09.2025. Verfasst von Mya C Schiess und 15 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorders Division, Department of Neurology, McGovern Medical School at UTHealth Houston, Houston, Texas, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research.
Abstract (Originalsprache)
Background
Neuroinflammation contributes to Parkinson's disease (PD) progression and motor dysfunction. Allogeneic human mesenchymal stem cells (allo‐hMSCs) may reduce neuroinflammation and improve motor symptoms.
Objectives
To evaluate the efficacy of repeated intravenous doses of 10 × 10 6 /kg allo‐hMSCs in improving motor symptoms in patients with PD (PwP).
Methods
In this phase 2, randomized, placebo‐controlled trial (November 2020–July 2023), mild‐to‐moderate PwP received either three allo‐hMSC infusions, one placebo followed by two allo‐hMSC infusions, or three placebo infusions at 18‐week intervals. Follow‐up lasted 88 weeks. The primary outcome was a >70% posterior probability (PP) of a difference in the proportion of participants with ≥5‐point improvement in OFF‐medication Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale‐Part III (MDS‐UPDRS‐III) at week 62. Bayesian analysis was conducted using R v4.2.0.
Results
Forty‐five PwP were enrolled. A larger proportion of subjects achieved a ≥5‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with placebo at week 62 (mean difference [MD]: 5.0%, PP = 93.7%), translating to a 16.9‐point improvement in MDS‐UPDRS‐III in the three‐infusion arm compared with a 14.6‐point improvement in the placebo arm. Conversely, fewer subjects in the two‐infusion arm compared with placebo showed ≥5‐point improvement at week 62 (MD: –62.4%, PP ≥ 99.9%), translating to only a 3.9‐point improvement in MDS‐UPDRS‐III in the two‐infusion arm. However, improvement in MDS‐UPDRS‐III was seen across all treatment arms. Adverse events were mild and transient.
Conclusions
Three infusions of 10 × 10 6 allo‐hMSCs/kg improved motor function in mild‐to‐moderate PwP, while two infusions showed less improvement than placebo. To address this discrepancy, future studies should conduct functional potency assays to understand batch‐to‐batch variability affecting clinical efficacy. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Movement Disorders Division, Department of Neurology, McGovern Medical School at UTHealth Houston, Houston, Texas, USA.
- Center for Clinical Research & Evidence-Based Medicine, Department of Pediatrics, McGovern Medical School at UTHealth Houston, Houston, Texas, USA.
- Institute for Stroke and Cerebrovascular Diseases, McGovern Medical School at UTHealth Houston, Houston, Texas, USA.
- Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, McGovern Medical School at UTHealth Houston, Houston, Texas, USA.
- Immunology & Organ Transplantation Division, Department of Surgery, McGovern Medical School at UTHealth Houston, Houston, Texas, USA.
- Movement Disorders Division, Department of Neurology, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Mya C Schiess, Jessika Suescun, Juan D Martinez-Lemus, Charles Green, Tia S Thomas, Mohammad Shahnawaz, Emily Tharp, Jerome G Saltarrelli, Christopher Adams, Marie-Francoise Doursout, Elsa M Rodarte, Sean I Savitz, Timothy M Ellmore
Förderung
- Michael J. Fox Foundation for Parkinson's Research
Zitieren
APA
Schiess, M. C., Suescun, J., Martinez-Lemus, J. D., Green, C., Thomas, T. S., Shahnawaz, M., Tharp, E., Satani, N. B., Saltarrelli, J. G., Adams, C., Doursout, M. F., Thyne, V., Abuamouneh, R., Rodarte, E. M., Savitz, S. I., & Ellmore, T. M. (2025). Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial. Movement Disorders, 40(12), 2688-2699. https://doi.org/10.1002/mds.70028
Vancouver
Schiess MC, Suescun J, Martinez-Lemus JD, Green C, Thomas TS, Shahnawaz M, et al. Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial. Movement Disorders. 2025;40(12):2688-2699. doi:10.1002/mds.70028
BibTeX
@article{Schiess2025,
author = {Schiess, Mya C and Suescun, Jessika and Martinez-Lemus, Juan D and Green, Charles and Thomas, Tia S and Shahnawaz, Mohammad and Tharp, Emily and Satani, Nikunj B and Saltarrelli, Jerome G and Adams, Christopher and Doursout, Marie-Francoise and Thyne, Vanessa and Abuamouneh, Rula and Rodarte, Elsa M and Savitz, Sean I and Ellmore, Timothy M},
title = {Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial},
journal = {Movement Disorders},
year = {2025},
volume = {40},
number = {12},
pages = {2688--2699},
doi = {10.1002/mds.70028}
}
EUVIMED